Table 5 Oncological and functional outcomes of 100 bladder cancer patients
Variables | Overall (n = 100) | Three-port group (n = 55) | Five-port group (n = 45) | P value |
|---|---|---|---|---|
Cancer-specific mortality for 2Â years, [n (%)] | 4 (4.00) | 2 (3.64) | 2 (4.44) | 0.837 |
Noncancer-specific mortality for 2Â years, [n (%)] | 7 (7.00) | 3 (5.45) | 4 (8.89) | 0.503 |
Daytime incontinence at 12Â months, [n (%)] | Â | Â | Â | 0.862 |
 0–1 pad/day | 86 (86.00) | 47 (85.45) | 39 (86.67) |  |
  > 1 pad/day | 14 (14.00) | 8 (14.55) | 6 (13.33) |  |
Nighttime incontinence at 12Â months, [n (%)] | Â | Â | Â | 0.716 |
 0–1 pad/day | 67 (67.00) | 36 (65.45) | 31 (68.89) |  |
  > 1 pad/day | 33 (33.00) | 19 (34.55) | 14 (31.11) |  |
Neobladder capacity at 12 months, [mean ± SD (range), mL] | 421.10 ± 46.56 (360–500) | 425.45 ± 51.24 (360–500) | 415.78 ± 40.03 (360–480) | 0.303 |